As part of the Synthon Group, Synthon Biopharmaceuticals is well-positioned to build on the success, global infrastructure and organization of the financially strong, privately held parent company.
In terms of commercializing its programs, Synthon chooses the optimum timing to partner each program. This might involve: taking a given product all the way to market or, alternatively, to partnering a technology or pipeline project at the appropriate stage or value inflection point.
Synthon develops next generation ADC products, both independently and in collaboration/ partnerships with biopharmaceutical companies that have suitable cancer antibody programs. We also consider in-licensing antibodies.
We welcome business opportunity proposals that may be complementary to our portfolio and fit with our strategy. For collaborative or (in/out) licensing opportunities or other partnering opportunities, please contact us.contact us